Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure

Therapy resistance and disease recurrence remain major challenges across cancer types despite substantial advances in targeted therapy, chemotherapy, and immunotherapy. In many clinical settings, treatments successfully engage stress and death signaling pathways and produce rapid tumor regression, yet complete and durable eradication is uncommon. A consistent pattern emerges in which most tumor cells are eliminated while a small fraction survives, persists as residual disease, and later drives relapse. These observations suggest that failure is not always due to the absence of death pathways, but rather to incomplete execution. Here, we synthesize emerging evidence supporting the view that regulated cell death operates as a threshold-governed, highly plastic process. Apoptosis, ferroptosis, and inflammatory death programs remain largely intact in many tumors but are tightly controlled by buffering networks that regulate mitochondrial commitment, redox balance, metabolic state, and inflammatory signaling. Under therapeutic pressure, cancer cells frequently activate proximal death signaling without progressing to irreversible collapse. Sublethal engagement can generate stressed but viable cell states that contribute to drug tolerance, minimal residual disease, and later resistance evolution. Clinical data across hematologic and solid malignancies reinforce this framework. Biomarkers of pathway activation often correlate with early response but do not reliably predict long-term benefit. Dose limitations, treatment interruptions, and adaptive rewiring further allow surviving populations to recover and expand. We propose that execution depth, rather than pathway activation alone, represents a critical determinant of durable response. This perspective supports therapeutic strategies that simultaneously drive death signaling while disabling buffering systems, prevent adaptive state transitions, and incorporate immune-mediated clearance to achieve sustained tumor elimination.